A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells

Melanoma Research

Volumn 18, Issue 2, 2008, Pages 73-84

  Schwenkert, Michael ^a   Birkholz, Katrin ^a   Schwemmlein, Michael ^a   Kellner, Christian ^a   Kügler, Markus ^a   Peipp, Matthias ^b   Nettelbeck, Dirk M ^c   Schuler Thurner, Beatrice ^a   Schaft, Niels ^a   Dörrie, Jan ^a   Ferrone, Soldano ^d   Kämpgen, Eckhart ^a   Fey, Georg H ^a,e  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Antibody therapeutics; Cyclosporin A; Exotoxin A; High molecular eight melanoma associated antigen; Immunotoxin; Melanoma; Melanoma associated chondroitin sulfate proteoglycan

Indexed keywords

CYCLOSPORIN A; HYBRID PROTEIN; IMMUNOTOXIN; PROTEOCHONDROITIN SULFATE; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENTIATION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL;

ADP RIBOSE TRANSFERASES; APOPTOSIS; BACTERIAL TOXINS; CELL LINE, TUMOR; CYCLOSPORINE; CYTOTOXICITY, IMMUNOLOGIC; EXOTOXINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; IMMUNOTOXINS; MELANOMA; PROTEOCHONDROITIN SULFATES; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED; VIRULENCE FACTORS;

EID: 40849085210     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3282f7c8f9     Document Type: Article

References (50)

1. Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001; 14:280-290.
2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
3. Schultz ES, Schuler G. Malignant melanoma. Diagnosis and therapy. HNO 2005; 53:928-939.
4. Helmbach H, Sinha P, Schadendorf D. Human melanoma: drug resistance. Recent Results Cancer Res 2003; 161:93-110.
5. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 2004; 24:267-296.
6. Smith FO, Rauch C, Williams DE, March CJ, Arthur D, Hilden J, et al. The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Blood 1996; 87:1123-1133.
7. Ferrone S, Chen ZJ, Liu CC, Hirai S, Kageshita T, Mittelman A. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma. Pharmacol Ther 1993; 57:259-290.
8. Bumol TF, Wang QC, Reisfeld RA, Kaplan NO. Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc Natl Acad Sci USA 1983; 80:529-533.
9. Schrappe M, Bumol TF, Apelgren LD, Briggs SL, Koppel GA, Markowitz DD, et al. Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27. Cancer Res 1992; 52:3838-3844.
10. Sivam G, Pearson JW, Bohn W, Oldham RK, Sadoff JC, Morgan AC Jr. Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates. Cancer Res 1987; 47:3169-3173.
11. Hjortland GO, Garman-Vik SS, Juell S, Olsen OE, Hirschberg H, Fodstad O, et al. Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. J Neurosurg 2004; 100:320-327.
12. Pastan I, FitzGerald D. Pseudomonas exotoxin: chimeric toxins. J Biol Chem 1989; 264:15157-15160.
13. Seetharam S, Chaudhary VK, FitzGerald D, Pastan I. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J Biol Chem 1991; 266:17376-17381.
14. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345:241-247.
15. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18:1622-1636.
16. Peipp M, Kupers H, Saul D, Schlierf B, Greil J, Zunino SJ, et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res 2002; 62:2848-2855.
17. Tur MK, Huhn M, Thepen T, Stocker M, Krohn R, Vogel S, et al. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res 2003; 63:8414-8419.
18. Schwemmlein M, Peipp M, Barbin K, Saul D, Stockmeyer B, Repp R, et al. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells. Br J Haematol 2006; 133:141-151.
19. Schwemmlein M, Stieglmaier J, Kellner C, Peipp M, Saul D, Oduncu F, et al. A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells. Leukemia 2007; 21:1405-1421.
20. Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle WE, Thornton J, et al. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002; 8:3092-3099.
21. Parney IF, Kunwar S, McDermott M, Berger M, Prados M, Cha S, et al. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 2005; 102:267-275.
22. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003; 65:27-35.
23. Azemar M, Djahansouzi S, Jager E, Solbach C, Schmidt M, Maurer AB, et al. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat 2003; 82:155-164.
24. Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 2003; 9:2837-2848.
25. Singh R, Samant U, Hyland S, Chaudhari PR, Wels WS, Bandyopadhyay D. Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors. Mol Cancer Ther 2007; 6:562-569.
26. Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, et al. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 2006; 177:8822-8834.
27. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006; 6:559-565.
28. Fabricant RN, De Larco JE, Todaro GJ. Nerve growth factor receptors on human melanoma cells in culture. Proc Natl Acad Sci USA 1977; 74:565-569.
29. Chee DO, Boddie AW, Roth JA, Holmes EC, Morton DL. Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium. Cancer Res 1976; 36:1503-1509.
30. Bumol TF, Reisfeld RA. Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci USA 1982; 79:1245-1249.
31. Barth S, Huhn M, Matthey B, Klimka A, Galinski EA, Engert A. Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions. Appl Environ Microbiol 2000; 66:1572-1579.
32. Bruenke J, Fischer B, Barbin K, Schreiter K, Wachter Y, Mahr K, et al. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaR III (CD16) triggers effective lysis of lymphoma cells. Br J Haematol 2004; 125:167-179.
33. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184:39-51.
34. Ciechomska I, Legat M, Golab J, Wesolowska A, Kurzaj Z, Mackiewicz A, et al. Cyclosporine A and its non-immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells in vitro and in vivo studies. Int J Cancer 2005; 117:59-67.
35. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988; 85:5879-5883.
36. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-274.
37. Von Minckwitz G, Harder S, Hovelmann S, Jager E, Al-Batran SE, Loibl S, et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res 2005; 7:R617-R626.
38. Mosieniak G, Figiel I, Kaminska B. Cyclosporin A, an immunosuppressive drug, induces programmed cell death in rat C6 glioma cells by a mechanism that involves the AP-1 transcription factor. J Neurochem 1997; 68:1142-1149.
39. Ito C, Ribeiro RC, Behm FG, Raimondi SC, Pui CH, Campana D. Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells. Blood 1998; 91:1001-1007.
40. 2+ dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem J 1988; 255:357-360.
41. Andersson Y, Juell S, Fodstad O. Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin A immunotoxin. Int J Cancer 2004; 112:475-483.
42. Zunino SJ, Storms DH. Resveratrol-induced apoptosis is enhanced in acute lymphoblastic leukemia cells by modulation of the mitochondrial permeability transition pore. Cancer Lett 2006; 240:123-134.
43. Gothel SF, Marahiel MA. Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci 1999; 55:423-436.
44. Hamilton GS, Steiner JP. Immunophilins: beyond immunosuppression. J Med Chem 1998; 41:5119-5143.
45. Connern CP, Halestrap AP. Purification and N-terminal sequencing of peptidyl-prolyl cis-trans-isomerase from rat liver mitochondrial matrix reveals the existence of a distinct mitochondrial cyclophilin. Biochem J 1992; 284 (Pt 2):381-385.
46. Ohno N, Kreitman RJ, Saito T, Masamoto I, Uozumi K, Hanada S, et al. Augmentation of the activity of an immunotoxin, anti-Tac(Fv)-PE40KDEL, in T cell lines infected with human T cell leukemia virus type-I. Leuk Lymphoma 2002; 43:885-888.
47. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65:9328-9337.
48. Hrusak O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002; 16:1233-1258.
49. Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006; 10:257-268.
50. Ghali L, Wong ST, Tidman N, Quinn A, Philpott MP, Leigh IM. Epidermal and hair follicle progenitor cells express melanoma-associated chondroitin sulfate proteoglycan core protein. J Invest Dermatol 2004; 122:433-442.